Citryll’s team consists of seasoned scientists and pharmaceutical professionals experienced in the discovery and development of first in class medicines with a new mechanism of action like CIT-013
Helmuth van Es, Ph.D.
CEO, Executive Director
Helmuth van Es, Ph.D.
CEO, Executive Director
Helmuth is a co-founder of Galapagos, where he was Head of Science in Leiden, responsible for numerous discovery programmes many of which are now in clinical development. He co-founded Audion Therapeutics, Antabio, Effecta Pharma and Citryll. Audion Therapeutics is a clinical stage company focussed on small molecule treatments for acquired forms of hearing loss based in part on IP of co-founder Albert Edge at the MEEI in Boston. Eli Lilly and Inkef Capital are investors in Audion. He is non-executive director of Antabio ― a small molecule antibacterial company with headquarters in Toulouse, France, subsidiaries in the UK and US. Effecta is a UK based small molecule discovery company focussing on dengue and related flaviviral infections.
Renato Chirivi is co-founder of Citryll and previously CSO. He has been central, with CEO Helmuth van Es in bringing Citryll to its current clinical develpment status. He is the co-inventor of therapeutic anti-citrullinated protein antibodies (tACPA), antagonists of NET biology, and an expert on antibody discovery, engineering, production, and protein citrullination. He has numerous years of experience in cancer, neurobiology and molecular immunology which he gained at the Mario Negri Institute for Pharmacological Research in Italy, The Scripps research institute in California, USA, the Nijmegen Center for Molecular Life Sciences, and ModiQuest BV, the Netherlands. Renato is responsible for technology development, MoA programme of Citryll's NET antagonist, intellectual property and specific therapeutic areas.
Eric Meldrum has 12 years of drug discovery experience at GSK in Switzerland and the UK. Until 2005 he was head of the Asthma and Rhinitis Disease Biology Department responsible for drug development up to Phase 2 proof of concept. Since then, Eric has been active as CSO in several biotech companies and brings Citryll a depth of experience in translational approaches to prioritise therapeutic opportunities and the strategic considerations behind successfully enhancing asset value and progression to clinical proof of concept. He was most recently CSO at ENYO Pharma, a French biotech currently in Phase 2 in Chronic Hepatitis B and NASH. Eric is responsible for the overall preclinical and clinical scientific and therapeutic strategy and to develop partnerships with pharma.
Marlon is founding partner of F.institute, a full service finance boutique dedicated to companies in the life sciences sector. Having more than 25 years of experience in financial management from large enterprises to venture funds and small technology companies, he acts as part time CFO for Citryll.
Next to Citryll, Marlon is also CFO of other leading life science ventures. He provides critical support in raising capital investments and delivering high quality information to all stakeholders.
Patrick Round graduated as a physician from Charing Cross Hospital Medical School in 1982. He has 30 years experience in the pharmaceutical industry starting at Novo Nordisk and Glaxo Wellcome; was Chief Medical Officer at Celltech, Cambridge Antibody Technology and Xention.
Over the past 12 years he has taken the role of Chief Medical Officer at a number of biotech start-up companies across a wide range of therapeutic areas including BVG portfolio companies Dezima and NorthSea Therapeutics. He is currently also consulting for Staten Biotechnology.
Since 2013 Leonie is working as an independent Clinical Research Executive for (academic) hospitals (Amsterdam UMC, Dutch Cancer Institute, UMC Utrecht, Radboud University) and biopharmaceutical companies (Roche, Enceladus, Arthrogen, Audion). Before being self-employed she headed the Clinical Operations Department at Roche Pharmaceuticals. She has > 20 years experience in biopharmaceutical research covering phase I-IV trials (industry and academically driven), in a wide variety of disease categories.
Leonie was board member of the Dutch Association of Pharmaceutical Medicine from 2012-2018 and member of several task forces within the Dutch Clinical Research Foundation.
Paul has over 30 year’s experience in the pharmaceutical industry in Oncology and Autoimmune Diseases. He held various positions with increasing project and management responsibilities at Organon, Schering Plough, MSD, Janssen Pharmaceuticals, Aduro Biotech, and AIMM Therapeutics.
Paul has a strong passion for science and is an expert in translating fundamental research into drug discovery and development solutions, building translational flowcharts for drug discovery and identification of (bio)markers for drug development both in small molecule and biologic programs. His work have been critical for the now FDA and EMA approved BTK inhibitor acalabrutinib, the CD27 agonist antibody program (MK-5890) currently in phase 2 clinical studies at Merck & Co and anti-APRIL antibody (BION-1301) now in development for treatment of IgA Nephropathy at Chinook Therapeutics.
Peter has over twenty years’ experience in working in the R&D of the international pharmaceutical companies MSD/Organon, Khondrion and Aduro Biotech Europe, The Netherlands. At Aduro, a company advancing novel antibody therapies for immune-oncology Peter served as the Bioanalytical Lead and contributed extensively in the development of two clinical and one pre-clinical stage antibodies APRIL (BION-1301), CTLA-4 (ADU-1604) and SIRP (ADU-1805), respectively.
Peter’s contribution at Khondrion in the development of unique live-cell imaging patient derived bioassays led to the selection of clinical candidate KH176 (Sonlicromanol), which was granted an orphan drug designation by EMA/FDA and entered Phase IIb KHENERGYZE study to treat a range of mitochondrial diseases. At MSD/Organon, where he headed the cell-based bioanalytical group, he gained a lot of expertise in the performance of bioanalysis of samples from (pre)clinical trials up to Phase III with investigational biological pharmaceuticals in compliance to GLP, which resulted in the launch of Elonva®.
Prior to joining MSD/Organon, Peter worked at the Wageningen University Research Centre and at the Department of Human Genetics at the Radboud University Medical Centre Nijmegen, respectively. At Nijmegen he contributed substantially to the founding of the Nijmegen DNA diagnostic services.
Maarten performed his Ph.D. research at the University Medical Center Utrecht (The Netherlands), Laboratory of Translational Immunology under supervision of Professor Linde Meyaard, working on immune regulation in autoimmune diseases with the focus on inhibitory receptors and NETosis.
Maarten is responsible for further unravelling the mechanism of action (MoA) of Citryll’s antibody drug candidate, the incorporation of new MoA insight into the drug development plan and identifying new therapeutic applications for tACPA.
Sangeeta got her PhD from NCCS, Pune (India) where she studied host pathogen interactions. She moved to Finland for her postdoc where she joined Prof. Sirpa Jalkanen lab in Turku University and studied the role of Stabilin-1 molecule in Acute myeloid leukemia. Continuing her research in the Netherlands, she worked in the laboratory of Dr. Jeanette Leusen at the UMC Utrecht, where she developed expertise in antibody related work. She has a keen interest to pursue her career in the development of therapeutic antibodies and joined the Citryll team in October 2019. She is part of the mechanism of action team (MoA) which is focused on unravelling the working mechanism of Citryll’s lead antibody drug candidate CIT-013 and identifying its new therapeutic strategies applications.
Rezie has worked for >25 years in the pharmaceutical industry (Organon, MSD, Aspen) and has a wide experience in protein purifications and different analytical techniques, including 10 years in ELISA assay development & troubleshooting.
At Citryll she joined the bioanalytics team responsible for the development and qualification of CMC, PK and biomarker assays that will support the clinical trials.
Stephanie obtained her Ph.D. degree at the department of Experimental Rheumatology, part of the Radboud Institute for Molecular Life Sciences of the Radboud university medical center in Nijmegen. She studied the inhibition of synovitis, the driving force of osteoarthritis, either via neutralization of single inflammatory mediators or via application of versatile adipose-derived mesenchymal stem cells (ASCs) which broadly reduce synovial inflammation. She investigated the working mechanism of ASCs in experimental osteoarthritis, and clarified the close interaction of ASCs with neutrophils.
At Citryll, Stephanie focuses on elucidating the mechanism of action and the identification of new therapeutic applications for CIT-013.
Daphne graduated her Ph.D. at the University of Groningen under the supervision of prof. Anna Salvati. During her Ph.D project, she studied the endocytic mechanisms by which cell internalize nanoparticles using a genome-wide forward genetic screening method. She has a great interest in innate immunology and joined Citryll in January 2021. Here, she works within the Mechanism of Action team to provide insight on the working mechanism of CIT-013 and to investigate potential new therapeutic areas.
Tirza recently got her bachelor’s degree Biology and Medical Research at the Avans University. During a previously completed education clinical chemistry and hematology and various internships she has gained experience in molecular biology, protein chemistry, cell biology and assay development. Here at Citryll she is participating in both the mechanism of action (MoA) team where the working mechanism of CIT-013 is studied, and the bioanalytics team where assays are developed to support the clinical trials.
Stan is currently studying biomedical research at the Avans University of Applied Sciences. Here he followed the Honours program ‘Chance’ on climate discussion. To further challenge himself, he also participated in the excellent project where he looked at the anti-inflammatory effects of Sulforaphane. He is currently working as an intern within the Mechanism of Action team (MoA) to help further unravel the mechanism behind CIT-013.